Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MAGE-A3 vaccine |
Synonyms | |
Therapy Description |
Biropepimut-S (MAGE-A3 vaccine) is a large peptide vaccine containing a membrane translocation sequence that is delivered into the endoplasmic reticulum where it facilitates the formation of MHC class 1 complexes (PMID: 24520093, PMID: 25537079). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MAGE-A3 vaccine | GL-0817|Biropepimut-S | Biropepimut-S (MAGE-A3 vaccine) is a large peptide vaccine containing a membrane translocation sequence that is delivered into the endoplasmic reticulum where it facilitates the formation of MHC class 1 complexes (PMID: 24520093, PMID: 25537079). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02873819 | Phase II | MAGE-A3 vaccine Cyclophosphamide + Poly ICLC + Sargramostim | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | Completed | USA | POL | HUN | ESP | 3 |